ReviewDrug design, development and therapy2025
Engineered Delivery Systems for Chinese Herbal Medicine in Peripheral Nerve Regeneration: Challenges, Advances, and Future Perspectives.
Review in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral neuropathy (PN), characterized by sensory, motor, and autonomic dysfunction, presents a significant therapeutic challenge owing to its diverse etiologies, dynamic spatiotemporal injury microenvironment, and impermeable blood-nerve barrier (BNB). The current treatment is mainly palliative and symptom-focused, and fails to solve the core pathological complexity, including the heterogeneity of nerve injury, the conflicting phases of inflammation, repair, and fibrosis, and the imbalance of the microenvironment in chronic conditions such as diabetes. Chinese herbal medicine (CHM) has multiple benefits including neuroprotective, anti-inflammatory, anti-oxidant, and microenvironmental regulation. However, its clinical translation is hindered by poor bioavailability, non-targeted biodistribution, BNB exclusion, and physicochemical mismatches in multicomponent formulations. Preclinical studies suggest that engineered delivery systems could emerge as a transformative solution to these limitations. Nanocarriers penetrate the BNB via diffusion or ligand-mediated targeting, offering spatiotemporal control through a stimulus-responsive design. Hydrogels align their degradation processes with nerve regeneration and correct the imbalanced microenvironments. Degradable membranes offer localized, sustained release, whereas functionalized nerve conduits address structural defects and improve functional recovery beyond autograft limitations. Despite promising preclinical efficacy, clinical translation faces significant hurdles, including long-term biocompatibility concerns, inconsistent scalability in manufacturing, dosage optimization balancing efficacy and cytotoxicity, dependence on external stimuli, and a lack of standardized regulatory frameworks. Overcoming these challenges requires interdisciplinary collaboration to advance intelligent multifunctional designs, scalable production, and rigorous validations. Based on compelling preclinical data, engineered CHM delivery systems are hypothesized to have enormous potential to transform PN management from palliative care to restorative treatment and establish a new framework in precision neurology.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.